Loading...

CRDF CARDIFF ONCOLOGY INC Product Launches 8-K Filing

CRDF

CRDF

CARDIFF ONCOLOGY INC

(CRDF)

2024 8-K

Show Summary

Summary

Financial Statements

Financial Results

By-law Amendments

Positive Trial Data

Q2 Financial Results

Earnings Reports

Annual Meeting of Stockholders

Amendment and Stock Options

Earnings Reports

Conference Presentation

Financial Results and Clini...

Regulation FD Disclosure

Financial Results and Certi...

Stock Options Granted

Annual Meeting of Stockholders

Earnings Reports

Regulation FD Disclosure

Earnings Reports

Appointment of Chief Medica...

External Links:

Cardiff Oncology announced positive initial data from a Phase 2 clinical trial for onvansertib in treating RAS-mutated metastatic colorectal cancer, with a conference call scheduled for December 10, 2024.

AI Assistant

CARDIFF ONCOLOGY INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.